Drug loading and elution from a phosphorylcholine polymer-coated coronary stent does not affect long-term stability of the coating in vivo.
A drug eluting coronary stent was developed for use in preclinical and clinical trial evaluation. The stent was coated with a phosphorylcholine (PC)-based polymer coating containing the cell migration inhibitor batimastat. A pharmacokinetic study was conducted in a rabbit iliac model using (14)C-radiolabeled version of the drug; this showed the drug release to be first order with 94% of it being released within 28 days. Unloaded and drug-loaded stents were implanted in a porcine coronary artery model; a number were explanted at 5 days and scanning electron microscopy was used to show that the presence of the drug did not affect the rate of stent endothelialization. The remainder of the stents were removed after 6 months and the stents carefully removed from the arterial tissue. Fourier-transform infrared (FT-IR) spectroscopy (both attenuated total reflectance and microscopic imaging) was used to show the presence of the PC coating on control unloaded, drug-loaded and explanted stents, providing evidence that the coating was still present. This was further confirmed by use of atomic force microscopy (AFM) amplitude-phase, distance (a-p,d) curves which generated the characteristic traces of the PC coating. Further AFM depth-profiling techniques found that the thicknesses of the PC coatings on an control unloaded stent was 252+/-19 nm, on an control batimastat-loaded stent 906+/-224 nm and on an explanted stent 405+/-224 nm. The increase in thickness after the drug-loading process was a consequence of drug incorporation in the film, and the return to the unloaded dimensions for the explanted sample indicative of elution of the drug from the coating. The drug delivery PC coating was therefore found to be stable following elution of the drug and after 6 months implantation in vivo.
Lewis
Andrew L
AL
Biocompatibles UK Ltd, Farnham Business Park, Farnham, Surrey, England. andrew_lewis@biocompatibles.co.uk
Willis
Sean L
SL
Small
Sharon A
SA
Hunt
Stuart R
SR
O'byrne
Vincent
V
Stratford
Peter W
PW
D000818:Animals; D001807:Blood Vessel Prosthesis; D020099:Coated Materials, Biocompatible / Q000737:chemistry* / Q000493:pharmacokinetics; D003331:Coronary Vessels / Q000166:cytology / Q000187:drug effects / Q000378:metabolism* / Q000601:surgery; D004343:Drug Implants / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D004355:Drug Stability; D020007:Implants, Experimental; D008422:Materials Testing; D010649:Phenylalanine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics*; D010767:Phosphorylcholine / Q000737:chemistry*; D015607:Stents; D013552:Swine; D013876:Thiophenes / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*
D020099:Coated Materials, Biocompatible; D004343:Drug Implants; D013876:Thiophenes; D010767:Phosphorylcholine; D010649:Phenylalanine; C080985:batimastat